DR DR DR METABOLIC SOLUTIONS FOR VASCULAR AND MEDICAL FOODS | EB-N3 EB-N5 EB-N6 NEUROPATHIC CONDITIONS Therapeutic Active Pharmaceutical Ingredient Guide EB-N3 DR EB-N5 DR EB-N6 DR ACTIVE INGREDIENT DESCRIPTION / / Nitric oxide and nerve blood flow L-methylfolate calcium [active folate (pure crystalline)] + Delayed Release – Homocysteine levels Peripheral nerve protein synthesis Methylcobalamin [active vitamin B ] + PATHOLOGY OF 12 – Homocysteine levels Advanced glycation end products PERIPHERAL NEUROPATHY Pyridoxal 5'-phosphate [active vitamin B ] – 6 – Homocysteine levels Peripheral nerve blood flow The active pharmaceutical grade Alpha-lipoic acid [antioxidant] + – Oxidative stress ingredients work synergistically to help Cholecalciferol [active vitamin D ] Nerve growth factor normalize and optimize metabolic 3 + factors involved in peripheral nerve and Benfotiamine [active vitamin B 1] – Advanced glycation end products vascular health. Riboflavin [active vitamin B 2] – Homocysteine levels PROPOSED PATHOPHYSIOLOGY OF DIABETIC PERIPHERAL NEUROPATHY 1 Causes are thought to be a multifactorial metabolic process that deteriorates vascular and neuronal tissues. EB-N3 DR EB-N5 DR EB-N6 DR * * * mia Neur Delayed Release Delayed Release Delayed Release che onal l Is De P5P na Redu my L-Methylfolate ro ced eli Benfotiamine eu N na Alpha-lipoic acid N er ti Alpha-lipoic acid L-methylfolate calcium ........6 mg L-methylfolate calcium ........6 mg L-methylfolate calcium ........ 6 mg n/ ve on io G /O Cholicalciferol t ro x c w i Methylcobalamin ..................4 mg Methylcobalamin ..................4 mg Methylcobalamin .................. 4 mg ri d t th a s t n F iv Pyridoxal 5'-phosphate .... 70 mg Pyridoxal 5'-phosphate .....70 mg Pyridoxal 5'-phosphate .....70 mg o Advanced a e c c t S o o t s r r Microvascular Glycation e Riboflavin .................................. 1.3 mg Alpha-lipoic acid .................600 mg Alpha-lipoic acid ..................600 mg a s V s Cholecalciferol .....................5000 IU Benfotiamine .........................300 mg Disease Endproducts Dosage: Dosage: Dosage: G l / u n r t Adult dose is 1 capsule twice Adult dose is 1 capsule twice a o o Adult dose is 1 capsule daily or as i t t Homocysteine/ t h Polyol c c i a daily with food or as directed daily with food or as directed o n directed by physician. F n MTHFR u f e Pathway s h t by physician. A.M. & P.M. dosing by physician. A.M. & P.M. dosing & y Polymorphism/ D w N l o is recommended. is recommended. a r it li G ri Vitamin D e c th e L-Methylfolate O o rv x Deficiency d e Methyl B L-Methylfolate id En N 12 e n/ d P5P Alpha-lipoic acid De tio ce pl ple u Riboflavin eti De ed on/ xide s/R Cholicalciferol Oxid Nitric O tres ative tive S YE FREE TEN FR ADE IN Stress xida D LU EE M O G DYE FREEGLUTEN FREE USA EE G E FR LUT RE M N DYE EN F ADE I It is crucial to correct the metabolic conditions that lead to the pathology present in diabetic Each vegan capsule Manufactured in compliance with current Good Manufacturing Practices [cGMP]. peripheral neuropathy. The therapeutic objective should not be just to improve symptoms, but is allergen and dye free. *Products feature delayed-release capsules for targeted delivery to promote tolerability. to NORMALIZE and OPTIMIZE all factors involved in nerve and vascular health. Actual product size and color may vary. 4 • EBM MEDICAL EBM MEDICAL • 5.